A newly identified and rare genetic variant slows the growth of mutated blood stem cells and reduces the risk of leukemia.
Preclinical AML studies showed palbociclib plus venetoclax produced stronger, more durable anti‑leukemia activity than venetoclax alone and may overcome resistance.
The chip can simulate breathing and lung disease for an individual, holding promise for testing personalized treatments for tuberculosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback